Is your memory loss part of normal ageing?

Learn more about mild cognitive impairment and ways to potentially slow its progress.

Mild cognitive impairment is a brain condition that involves subtle changes to your memory and thinking.1

The symptoms are more than what you might experience with normal ageing but not as severe as dementia.2

People with mild cognitive impairment are three to five times more likely to develop dementia.3

Symptoms of mild cognitive impairment

While it may be easy to dismiss symptoms of mild cognitive impairment as “just getting old”, ignoring any increasing or more frequent signs can generally hinder a proper diagnosis and opportunity to help manage the condition’s progression.

It’s always recommended that you chat to a medical professional if you notice yourself or a loved one experiencing any of the following symptoms4 more frequently or severely:

  • Forgetting important events or appointments
  • Losing items
  • Problems with language
  • Trouble paying attention
  • Greater difficulty with decision making
  • Visual perception changes, making it more difficult to judge distances and identify objects.

Ways to potentially slow mild cognitive impairment

Making lifestyle and diet changes under medical supervision can potentially slow the progression of mild cognitive impairment.5

These include:

  • Engaging in brain-stimulating activities such as learning a musical instrument or language
  • Eating a healthy diet providing a balanced mix of nutrients
  • Making regular exercise part of your routine, even if it’s a walk
  • Keeping in touch with friends and family, or joining a club, to keep up social engagement
  • And trying to get adequate quality sleep.

It’s also important to speak to your health care professional as they can do a thorough assessment to understand whether there are underlying causes that may be contributing to cognitive impairment.

How Souvenaid® can nutritionally support memory function

Souvenaid® is a medical drink that nutritionally supports memory function in the early stages of Alzheimer’s disease, the most common form of dementia.

Souvenaid has been proven to slow memory and cognitive decline by an average of 60 per cent in those with mild cognitive impairment due to Alzheimer’s disease when taken daily over three years6. (Individual results may vary.)

Over time, Alzheimer’s disease causes a loss of connections in the brain, resulting in impaired memory and cognition.

Souvenaid® contains Fortasyn® Connect, a unique combination of nutrients including DHA and EPA (omega-3 fatty acids), choline, uridine and B vitamins, formulated to nutritionally support the growth of brain connections.

It is available in a ready-to-drink liquid in vanilla, cappuccino and strawberry flavours and in powder format in two flavours: lemon and orange; and vanilla and banana.

Take it once daily for a delicious support in your life!

*This post is brought to you by Danone Souvenaid. Souvenaid® is a food for special medical purposes for the dietary management of early Alzheimer’s disease. This product does not cure or alleviate Alzheimer’s disease. Must be used under medical supervision. This article is not intended to be a substitute for medical advice; always consult your health care professional.


1 Dementia Australia, Mild cognitive impairment (MCI), retrieved May 2024 from https://www.dementia.org.au/brain-health/mild-cognitive-impairment-mci
2 Dementia Australia, Mild cognitive impairment (MCI), retrieved May 2024 from https://www.dementia.org.au/brain-health/mild-cognitive-impairment-mci
3 Health Direct, Worried about your memory?, retrieved May 2024 from https://www.healthdirect.gov.au/worried-about-your-memory
4 Dementia Australia, Mild cognitive impairment (MCI), retrieved May 2024 from https://www.dementia.org.au/brain-health/mild-cognitive-impairment-mci
5 Dementia Australia, Mild cognitive impairment (MCI), retrieved May 2024 from https://www.dementia.org.au/brain-health/mild-cognitive-impairment-mci
6 Soininen et al, 2020, 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer’s disease, Alzheimer’s & Dementia, Volume 17, Issue 1, 29-40, retrieved May 2024 from https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12172. Funded by Danone Nutricia Research and LipiDiDiet Consortium

SHARE THIS

RELATED ARTICLES